In:
American Journal of Nephrology, S. Karger AG, Vol. 34, No. 3 ( 2011), p. 256-267
Kurzfassung:
〈 i 〉 Background/Aims: 〈 /i 〉 Angiotensin-converting enzyme (ACE) inhibitors have cardioprotective properties and functional calcium-sensing receptors express in cardiac myocytes. 〈 i 〉 Methods: 〈 /i 〉 Rats were made uremic by 5/6 nephrectomy and treated as follows: uremic rats were fed on a regular diet (UC), uremic + enalapril (E), uremic + calcimimetic agent R-568 (R-568), and uremic + enalapril + R-568 (E+R-568). A group of normal rats served as controls (NC). 〈 i 〉 Results: 〈 /i 〉 Blood pressure (BP) and left ventricle mass were elevated significantly in the UC and R-568 groups compared with those in the NC group, but were indistinguishable from normal controls in the E and E+R-568 groups. Cardiac fibrosis was significantly increased in the UC group compared with that in the NC group. This increase was significantly attenuated in the R-568 and E groups, and the attenuation was further enhanced in the E+R-568 group. Factors associated with cardiac hypertrophy such as proliferating cell nuclear antigen, cyclin D1, and cyclin D2, as well as factors associated with cardiac fibrosis such as type I collagen, fibronectin, and transforming growth factor-β1 were significantly increased in the UC group compared with those in the NC group. Monotherapy with R-568 or E attenuated this increase and the combination further attenuated these measures. 〈 i 〉 Conclusions: 〈 /i 〉 Calcimimetics can suppress the progression of uremic cardiomyopathy and this effect is amplified when BP is controlled via renin-angiotensin system blockade.
Materialart:
Online-Ressource
ISSN:
0250-8095
,
1421-9670
Sprache:
Englisch
Verlag:
S. Karger AG
Publikationsdatum:
2011
ZDB Id:
1468523-1
